Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 46.51% is 13% above its 5-year average of 41.22%, near the high end of its 5-year range (3.41%–47.78%).
31.57% above its 12-month average of 35.35%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 45.24%.
GROSS MARGIN
46.51%
GROSS MARGIN AVG TTM
35.35%
GROSS MARGIN AVG 3Y
42.99%
GROSS MARGIN AVG 5Y
41.22%
GROSS MARGIN AVG 10Y
40.67%
GROSS MARGIN AVG 15Y
44.00%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.57%
CURRENT VS 3Y AVG
+8.19%
CURRENT VS 5Y AVG
+12.84%
CURRENT VS 10Y AVG
+14.37%
CURRENT VS 15Y AVG
+5.71%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-1.43%
vs the sector median at left
Market Cap
$87.86M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$88.21M
Gross Margin
40.32%
TTM Avg
35.69%
3Y Avg
34.43%
5Y Avg
37.90%
Market Cap
$84.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$84.70M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
Market Cap
$84.00M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$83.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$91.33M
Gross Margin
87.06%
TTM Avg
85.86%
3Y Avg
83.85%
5Y Avg
76.72%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CareCloud, Inc. (CCLD) | $86.69M | 46.51% | 35.35% | 42.99% | 41.22% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 100.00% | 100.00% | 100.00% | 100.00% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 40.32% | 35.69% | 34.43% | 37.90% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 82.44% | 83.07% | -40.55% | -241.44% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -736.46% | -368.23% | -290.99% | -1574.61% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.33M | 87.06% | 85.86% | 83.85% | 76.72% |
| Equillium, Inc. (EQ)vs › | $91.68M | 0.00% | 50.00% | 75.00% | 50.00% |
Gross Margin
46.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 45.24% |
| 2026-03-31 | 33.20% |
| 2025-12-31 | 3.41% |
| 2025-09-30 | 47.78% |
| 2025-06-30 | 47.11% |
| 2025-03-31 | 44.04% |
| 2024-12-31 | 46.87% |
| 2024-09-30 | 45.98% |
| 2024-06-30 | 45.74% |
| 2024-03-31 | 41.54% |
| 2023-12-31 | 40.27% |
| 2023-09-30 | 37.64% |
| 2023-06-30 | 40.48% |
| 2023-03-31 | 39.65% |
| 2022-12-31 | 39.85% |
| 2022-09-30 | 39.49% |
| 2022-06-30 | 41.48% |
| 2022-03-31 | 35.85% |
| 2021-12-31 | 35.40% |
| 2021-09-30 | 37.02% |
| 2021-06-30 | 39.72% |
| 2021-03-31 | 39.33% |
| 2020-12-31 | 40.76% |
| 2020-09-30 | 27.54% |
| 2020-06-30 | 35.86% |
| 2020-03-31 | 37.96% |
| 2019-12-31 | 40.31% |
| 2019-09-30 | 37.48% |
| 2019-06-30 | 31.96% |
| 2019-03-31 | 34.70% |
| 2018-12-31 | 37.55% |
| 2018-09-30 | 28.87% |
| 2018-06-30 | 50.09% |
| 2018-03-31 | 46.02% |
| 2017-12-31 | 50.72% |
| 2017-09-30 | 44.47% |
| 2017-06-30 | 46.08% |
| 2017-03-31 | 36.46% |
| 2016-12-31 | 30.64% |
| 2016-09-30 | 50.00% |
| 2016-06-30 | 55.48% |
| 2016-03-31 | 54.96% |
| 2015-12-31 | 56.03% |
| 2015-09-30 | 49.90% |
| 2015-06-30 | 51.17% |
| 2015-03-31 | 42.22% |
| 2014-12-31 | 33.81% |
| 2014-09-30 | 38.95% |
| 2014-06-30 | 57.44% |
| 2014-03-31 | 55.21% |
| 2013-12-31 | 63.59% |
| 2013-09-30 | 54.62% |
| 2013-06-30 | 60.23% |
| 2013-03-31 | 58.55% |
| 2012-12-31 | 59.31% |
| 2012-09-30 | 57.19% |
